US2008175824A1PendingUtilityA1

Co-culture of placental stem cells and stem cells from a second source

Assignee: HEIDARAN MOHAMMADPriority: Feb 13, 2002Filed: Oct 31, 2007Published: Jul 24, 2008
Est. expiryFeb 13, 2022(expired)· nominal 20-yr term from priority
A61P 43/00A61K 35/51C12N 5/0647C12N 2502/02G01N 33/56966C12N 2502/025C12N 5/0605A61K 35/50A61K 2035/124C12N 5/0607C12N 5/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.

Claims

exact text as granted — not AI-modified
1 .- 52 . (canceled) 
     
     
         53 . A composition comprising nucleated cells from human placental perfusate and stem cells from a second source, wherein said perfusate cells and stem cells from a second source, when cultured for a time and under conditions that allow the formation of colony-forming units, together produce more colony-forming units than a number of placental perfusate cells equivalent to the number of perfusate cells and stem cells from a second source, or a number of stem cells from a second source equivalent to the number of cells in the perfusate cells and stem cells from a second source, alone. 
     
     
         54 . A composition comprising human stem or progenitor cells and isolated human placental stem cells, wherein said placental stem cells are obtained from a placental that has been drained of cord blood and flushed to remove residual blood, and wherein said placental stem cells are:
 CD200 +  and HLA-G + ;   CD73 + , CD105 +  and CD200 + ;   CD200 +  and OCT-4 + ;   CD73 + , CD105 +  and HLA-G + ;   CD73 + , CD105 +  and facilitate the formation of embryoid-like bodies in a population of isolated placental cells comprising said stem cells, when said population is cultured under conditions that allow the formation of embryoid-like bodies; or   OCT-4 +  and facilitate the formation of embryoid-like bodies in a population of isolated placental cells comprising said stem cells, when said population is cultured under conditions that allow the formation of embryoid-like bodies.   
     
     
         55 . A method of transplantation, comprising transplanting to a recipient a combination of placental perfusate cells and stem cells from a second source, wherein said combination, when transplanted, results in enhanced engraftment compared to transplantation of a number of placental perfusate cells equivalent to the number of cells in the combination, or stem cells from a second source equivalent to the number of cells in the combination, alone.

Join the waitlist — get patent alerts

Track US2008175824A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.